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ContractionMuscle contains various fatty acid transporters (CD36, FABPpm, FATP1, FATP4). Physiological stimuli
(insulin, contraction) induce the translocation of all four transporters to the sarcolemma to enhance
fatty acid uptake similarly to glucose uptake stimulation via glucose transporter-4 (GLUT4) translo-
cation. Akt2 mediates insulin-induced, but not contraction-induced, GLUT4 translocation, but its
role in muscle fatty acid transporter translocation is unknown. In muscle from Akt2-knockout mice,
we observed that Akt2 is critically involved in both insulin-induced and contraction-induced fatty
acid transport and translocation of fatty acid translocase/CD36 (CD36) and FATP1, but not of translo-
cation of fatty acid-binding protein (FABPpm) and FATP4. Instead, Akt2 mediates intracellular reten-
tion of both latter transporters. Collectively, our observations reveal novel complexities in signaling
mechanisms regulating the translocation of fatty acid transporters in muscle.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Fatty acids and glucose are essential fuels for skeletalmuscle. The
transport of these substrates into this tissue occurs via highly regu-
lated, protein-mediated processes. Specifically, in skeletal muscle,
glucose transport is facilitated by glucose transporter-4 (GLUT4)
(cf. [1,2]),while fatty acid transport is facilitatedbyanumberof fatty
acid transporters, including fatty acid translocase/CD36 (CD36),
plasma membrane associated fatty acid-binding protein (FABPpm),
and selected fatty acid transport proteins (FATP1 and -4) (cf. [3]).
Acute changes in glucose utilization induced by selected metabolic
stimuli (insulin, 50AMP-activated protein kinase (AMPK) activation,
muscle contraction) are largely attributable to the translocation of
GLUT4 from intracellular depots to the cell surface, thereby increas-
ing the rate of glucose transport [2,4]. In recent years, similar meta-
bolic flexibility has been shown for FAT/CD36, as this fatty acidtransport protein is also induced to translocate to the cell surface
by the same metabolic stimuli (cf. [3]).
The signaling mechanisms involved in GLUT4 translocation to
the sarcolemma in response to selected metabolic perturbations
are well characterized [2,4]. In contrast, the signaling pathways
involved in the translocation of fatty acid transporters to the sar-
colemma are largely unknown. Nevertheless, CD36 translocation
appears to share, in part, a signaling pathway that may be similar
to GLUT4. For example, both GLUT4 and CD36 are recruited from
intracellular pools to the sarcolemma by insulin-stimulated activa-
tion of phosphatidylinositol-3-kinase (PI3K) [5,6]. Similarly, mus-
cle contraction and the activation of muscle AMPK by 5-
aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)
induce the translocation of both GLUT4 and CD36 to the sar-
colemma [3,5,7,8], as well as that of a number of other fatty acid
transporters, namely FABPpm, FATP1, FATP4, but not FATP6 [7].
Despite the comparable responses of GLUT4 and fatty acid
transporters to metabolic stimulation and the apparent sharing
of PI3K signaling, there is evidence that the GLUT4 and the fatty
acid transporter signaling pathways diverge at some point. For
example, in insulin resistant, obese Zucker rats and in Zucker dia-
betic fatty acid rats GLUT4 is retained intracellularly [9], while
CD36 is permanently relocated to the sarcolemma [10], resulting
in an in an inverse relationship between sarcolemmal GLUT4 and
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insulin-stimulated GLUT4 translocation is impaired [9], while
contraction-stimulated GLUT4 translocation is normal [1]. More-
over, both insulin and contraction-induced CD36 translocation
are impaired in obese Zucker rat muscle [12]. Since FABPpm
translocation is not impaired in these animals, it appears that
CD36 and FABPpm may be regulated by different insulin and
contraction-mediated signaling pathways [12]. Collectively, these
observations indicate that the signaling pathways involved in the
translocation of these transporters differ from those involved in
GLUT4 translocation. In addition, their signaling pathways remain
obscure, and there may be specific signaling pathways for the dif-
ferent fatty acid transporters.
Akt is a family of protein kinases regulating multiple anabolic
pathways, and at present there are three isoforms described. In
general, Akt1 mediates hypertrophic signaling, Akt2 is involved
in insulin signaling, whereas much less is known about Akt3
[13]. In the past few years it has become evident that Akt2 con-
tributes to the regulation of lipid metabolism. For example, Akt2
signaling promotes mammary gland [14] and hepatic triacylglyc-
erol accumulation [15–17]. Yet, it is unknown whether the regula-
tion of lipid metabolism by Akt2 signaling extends to the fatty acid
transport process. Moreover, whether a signaling divergence
between GLUT4 and selected fatty acid transporters, or among dif-
ferent fatty acid transporters, occurs at the level of Akt2 is also
unknown. Therefore, in the present study, we investigated whether
Akt2 is involved in the insulin-, and/or contraction-mediated sig-
naling for fatty acid transport and fatty acid transporter transloca-
tion (CD36, FABPpm, FATP1 and -4), and compared this to glucose
transport and GLUT4 translocation.
2. Materials and methods
2.1. Animals
Akt2-knockout (KO) mice were a gift from Pfizer Inc. (New York,
NY [18]) and corresponding DBA/1 wildtype (WT) mice were pur-
chased from Jackson Laboratories (Bar Harbor, Maine). WT and KO
female mice were carefully matched for age (8 weeks). At this age,
the body weights of WT mice (20.8 ± 0.7 g) were greater than in KO
mice (16.3 ± 0.5 g) P < 0.05, as has been reported by others [18,19].
The animals were housed in controlled temperature and humidity
conditions on a 12:12-h light–dark cycle and were given standard
laboratory chow and water ad libitum. Mice were anesthetized
with sodium pentobarbital (6 mg/100 g body wt ip; MTC Pharma-
ceuticals, Cambridge, ON), and all procedures were approved by
the University of Guelph Animal Care Committee.
2.2. Genotyping
Genotypes of KO mice were confirmed using standard DNA iso-
lation and PCR methods (Extract-N-Amp, Sigma–Aldrich, St. Louis,
MO) using forward 50-GCA-GGA-TCT-CCT-GTC-ATC-TCA-CC-30 and
reverse 30-GAT-GCT-CTT-CGT-CCA-GAT-CAT-CC-50 primer sets tar-
geted towards the neo cassette.
2.3. Experimental treatment
Basal tail vein glucose concentrations were determined using a
glucose meter (Ascensia Elite XL, Bayer Inc., Toronto, ON).
Intraperitoneal glucose and insulin tolerance tests were conducted
in separate groups of overnight fasted WT and KO animals. Mice
were injected intraperitoneally with either glucose (0.75 g/kg body
wt) or insulin (1.0 U/kg body wt) and blood glucose was recorded
at 15, 30, 45, 90 and 120 min. To examine the effects of insulinand muscle contraction on glucose and fatty acid transport and
transporters, fasted WT and KO mice were assigned to the follow-
ing groups: (i) control (no treatment), (ii) insulin treatment for
15 min (Humulin, 1.0 U/kg body wt, ip; Eli Lilly, Toronto, ON), or
(iii) muscle contraction via the sciatic nerve (train delivery
100 Hz/3 s at 5 V, train duration 200 ms, pulse duration 10 ms)
applied for 3 repetitions of 5 min with 2 min of rest between stim-
ulations [7]. Following treatment periods, hindlimb muscles were
immediately harvested for isolation of giant sarcolemmal vesicles
or were freeze-clamped in liquid N2 for muscle homogenate
preparation.
2.4. Isolation of giant sarcolemmal vesicles and substrate transport
Fatty acid and glucose transport as well as sarcolemmal pres-
ence of transport proteins were determined in giant sarcolemmal
vesicles isolated from hindlimb muscles [7,20]. Vesicle protein
yield was determined using the bicinchoninic acid assay. Vesicles
were used immediately for substrate transport assays [7,20].
2.5. Western blotting
Protein expression was determined in giant sarcolemmal vesi-
cles and muscle homogenates via Western blotting [7,20]. Blot-
ting protocols with antibodies against total Akt2, AS160, AMPK,
phosphorylated Akt-Thr308, AS160-Thr642, AMPK-Thr172 (Cell Sig-
naling, Danvers, MA), CD36, FATP1, and -4 (Santa Cruz Biotech-
nology, Santa Cruz, CA, [21]) and GLUT4 (Millipore, Temecula,
CA) were performed according to manufacturer’s instructions.
Antibodies against FABPpm were kindly donated by Dr. J.
Calles-Escandon, Wake Forest University. Following incubation
with secondary antibodies, membranes were detected and quan-
tified using chemiluminescence (Perkin Elmer Life Science, Bos-
ton, MA) and ChemiGenius2 Bioimaging (SynGene, Cambridge,
UK). Equal loading of protein was confirmed via Ponceau-S
staining.
2.6. Statistics
All data are reported as mean ± S.E.M. and were analyzed using
analysis of variance and Fisher’s LSD post hoc test when appropri-
ate. Significance was accepted at P < 0.05.
3. Results
3.1. Akt2-KO phenotype
Pre-diabetic state: Basal blood glucose concentrations
were lower in WT (4.2 ± 0.2 mM) than in Akt2-KO animals
(5.4 ± 1.0 mM, P < 0.05), and Akt2-KO mice exhibited whole
body glucose intolerance (Fig. 1A). These observations confirm
previous results reported elsewhere for these animals
[18,19,22].
3.2. Expression of insulin signaling proteins, AMPK and substrate
transporters
As expected in Akt2-KO mice, Akt2 protein was not detected
(Fig. 1B). The presence of insulin signaling proteins insulin receptor
substrate-1, phosphatidylinositol-3 kinase and AS160 (the down-
stream target of Akt2) in skeletal muscle did not differ between
WT and Akt2-KO mice (Fig. 1B). Neither the metabolic regulator
AMPK (Fig. 1B), nor GLUT4 or fatty acid transporter (CD36,
FABPpm, FATP1 and -4) protein contents differed between WT
and Akt2-KO mice (Fig. 1C).
Fig. 1. Effects of Akt2 ablation on glucose tolerance (A), as well as expression of selected signaling proteins (B) and substrate transporters (C) in skeletal muscle.
Representative Western blots are displayed. Mean ± S.E.M., n = 4–6 independent determinations for each measurement. P < 0.05, KO vs WT.
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Bolus administration of insulin (15 min) was used to examine
insulin’s effects on skeletal muscle Akt2, AS160 and AMPK phos-
phorylation. In addition, phosphorylation of these proteins was
examined in response to electrically stimulated muscle contraction
(15 min). We confirmed the expected effects of Akt2 ablation in
skeletal muscle, namely impaired insulin-stimulated Akt phospho-
rylation Akt in Akt2-KO mice (P < 0.05, Fig. 2A, and [23]). Residual
Akt phosphorylation in Akt2-KO muscle is likely to be attributable
to phosphorylation of the other Akt isoforms [19]. Furthermore,
insulin-stimulated phosphorylation of AS160, the downstream tar-
get of Akt2, was completely abolished in Akt2-KO mice (Fig. 2B).
Hence, other Akt isoforms do not contribute to insulin-stimulated
AS160 phosphorylation.
Muscle contraction had a small but significant effect on Akt
phosphorylation in WT muscle (Fig. 2A). Furthermore, muscle con-
traction markedly stimulated AS160 phosphorylation in WT mus-
cle (Fig. 2B), in agreement with the notion that AS160 is a
convergence point of insulin and contraction signaling. Both
contraction-induced AS160 and AMPK phosphorylations were pre-
served in Akt2-KO muscle (Fig. 2B and C), thereby confirming that
Akt2 is not involved in contraction signaling. Finally, Akt2 is not
involved in basal AMPK phosphorylation, and as expected, insulin
stimulation did not alter AMPK phosphorylation (Fig. 2C).
3.4. Glucose transport and GLUT4 translocation in Akt2-KO muscle
Under basal conditions, glucose transport into giant vesicles
and sarcolemmal GLUT4 content were not different in WT and
Akt2-KO mice (Fig. 3A and B). As expected, in Akt2-KO muscle
insulin-stimulated glucose transport and GLUT4 translocation
were markedly blunted (Fig. 3A and B). In contrast, contraction-stimulated glucose transport and sarcolemmal GLUT4 content
were each increased comparably (P < 0.05) in WT and Akt2-KO
mice (Fig. 3A and B), in agreement with other observations in
Akt2-KO mice [24].
3.5. Fatty acid transport and transporters in Akt2-KO muscle
In giant vesicles from WT muscle, fatty acid transport was
markedly increased, either with insulin stimulation (+117%) or
with muscle contraction (+107%) (Fig. 4A). However in Akt2-KO
muscle, insulin and contraction were unable to stimulated fatty
acid transport (Fig. 4A).
We next examined whether the impairments in fatty acid trans-
port in Akt2-KO muscle were associated with concurrent alter-
ations in insulin-, and contraction-stimulated fatty acid
transporter translocation. Basal contents of sarcolemmal CD36
and FATP1 were not altered in Akt2-KO mice (Fig. 4B and C). In
contrast, basal levels of sarcolemmal FABPpm (+12%) and FATP4
(+38%) were increased in Akt2-KO mice (Fig. 4D and E).
In WT mice, insulin stimulation was associated with increased
sarcolemmal presence of all fatty acid transporters (CD36 (+77%),
FABPpm (+13%), FATP1 (+64%), and FATP4 (+54%)) (Fig. 4B–E), con-
firming previous observations [7]. In contrast in Akt2-KO mice,
insulin failed to stimulate CD36 and FATP1 translocation
(Fig. 4B and C). Moreover, insulin stimulation did not increase sar-
colemmal contents of FABPpm and FATP4 in Akt2-KO mice beyond
the increases observed under basal conditions (Fig. 4D and E).
Muscle contraction increased the sarcolemmal presence of all
fatty acid transporters in WT mice (CD36 (+101%), FABPpm
(+21%), FATP1 (+70%), and FATP4 (+50%)) (Fig. 4B–E), confirming
previous observations [7]. However, as with insulin stimulation,
muscle contraction in the Akt2-KO mice failed to induce CD36
and FATP1 translocation (Fig. 4B and C). In addition, muscle con-
Fig. 2. Effects of Akt2 ablation on insulin and contraction-stimulated phosphorylation of Akt at Thr308 (A), AS160 at Thr642 (B) and AMPK at Thr172 (C) in muscle. B: basal; I:
insulin; CT: contraction. Representative Western blots are displayed. Caveolin-3 was used as loading control for both the Akt-phospho-Thr308 and AS160-phospho-Thr642
blots. Mean ± S.E.M., n = 4–6 independent determinations for each measurement. *P < 0.05, KO vs WT; **P < 0.05, insulin vs basal or contraction vs basal within WT or within
Akt2-KO.
Fig. 3. Effects of Akt2 ablation on glucose transport into giant sarcolemmal vesicles (A) and sarcolemmal GLUT4 content (B) under basal conditions and after stimulation with
insulin or with muscle contraction. A representative Western blot is displayed with caveolin-3 as loading control. Mean ± S.E.M., n = 4–6 independent determinations for each
measurement. *P < 0.05, KO vs WT; **P < 0.05, insulin vs basal, or contraction vs basal within WT or within Akt2-KO.
2772 S.S. Jain et al. / FEBS Letters 589 (2015) 2769–2775traction also failed to increase sarcolemmal contents of FABPpm
and FATP4 in Akt2-KO mice beyond the increases observed under
basal conditions (Fig. 4D and E).
4. Discussion
We have examined the role of Akt2 in skeletal muscle on (a)
insulin- and contraction-stimulated fatty acid transport, and (b)
the translocation of fatty acid transport proteins to the sar-
colemma. For comparison we studied GLUT4-mediated glucose
uptake and confirm previous observations in Akt2-KO mice[18,19,22,25] that insulin-stimulated glucose transport and GLUT4
translocation are impaired, while contraction-stimulated glucose
transport and GLUT4 translocation are comparably up-regulated
in both WT and Akt2-KO mice. With respect to the fatty acid trans-
porters, we made several novel observations, which indicate that
their Akt2-dependent subcellular localization is regulated differ-
ently from that of GLUT4. Specifically, we demonstrate for the first
time the critical role of Akt2 signaling in both insulin-stimulated
and contraction-stimulated translocation of CD36 and FATP1. In
contrast, under basal conditions, Akt2 ablation releases the brake
on the subcellular retention of FABPpm and FATP4, allowing these
Fig. 4. Effects of Akt2 ablation on palmitate transport into giant sarcolemmal vesicles (A) and sarcolemmal contents of FAT/CD36 (B), FATP1 (C), FABPpm (D) and FATP4 (E)
under basal conditions and after stimulation with insulin or with muscle contraction. Representative Western blots and corresponding caveolin-3 blots as loading controls are
displayed. Mean ± S.E.M., n = 4–6 independent determinations for each measurement. *P < 0.05, KO vs WT; **P < 0.05, insulin vs basal, or contraction vs basal within WT or
within Akt2-KO.
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insensitive to further stimulation.
4.1. Basal, insulin and contraction-stimulated signaling, glucose
transport and GLUT4 translocation
As expected, Akt2-KO muscle exhibited impaired insulin signal-
ing as shown by the abolishment of insulin-induced AS160 phos-
phorylation. Consequently, in Akt2-KO mice whole body glucose
tolerance as well as insulin-stimulated glucose transport and
GLUT4 translocation in muscle were impaired. In contrast,
contraction-stimulated AMPK phosphorylation, AS160 phosphory-
lation, glucose transport and GLUT4 translocation were normal in
Akt2-KO muscle. Hence, insulin and contraction stimulate GLUT4
translocation via distinct signaling pathways: insulin-stimulated,
but not contraction-stimulated, GLUT4 translocation is dependent
on Akt2 [2,4,26,27]. The confirmation of these GLUT4 dynamicsalso indicates that giant vesicles are well-suited to study transloca-
tion processes in vitro [20]. We have previously shown that
increases in substrate transporter contents in these giant vesicles
are due to their translocation from intracellular depots [20].
4.2. Basal, insulin- and contraction-stimulated fatty acid transport and
sarcolemmal fatty acid transporters
In Akt2-KO muscle, total tissue expression of all four fatty acid
transporters was unaltered. Furthermore, in Akt2-KO muscle, insu-
lin or contraction failed to stimulate fatty acid transport and
translocation of CD36 and FATP1. Conversely, Akt2 ablation caused
an increase in sarcolemmal FABPpm and FATP4 in non-stimulated
muscle with no further increases in response to metabolic stimuli.
Hence, we propose the following novel roles of Akt2 in regulation
of muscle substrate transporter dynamics: Akt2 mediates translo-
cation of CD36 and FATP1 in response to both (i) insulin and (ii)
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of FABPpm and FATP4 under basal conditions. Moreover, the close
correlation between fatty acid transport dynamics and alterations
in sarcolemmal CD36 and FATP1, but not FABPpm and FATP4, indi-
cates that CD36 and/or FATP1 are the main fatty acid transporters
responsible for Akt2 regulation of muscle fatty acid transport.
Although prior work has shown that FATP1 is insulin-sensitive
[7,28], its fatty acid transport capacity is low [21] and it is gener-
ally poorly correlated with indices of fatty acid transport and meta-
bolism among metabolic heterogeneous muscle tissues [21,29].
Moreover, in muscle from CD36-KO mice, insulin, contraction/
exercise or the contraction-mimetic AMPK activator AICAR fail to
stimulate fatty acid transport [30,31], despite the presence of all
other fatty acid transporters. Together, these observations indicate
that muscle metabolic flexibility is largely rendered by CD36.
Below, we will further speculate on the three novel roles of Akt2
in regulation of muscle substrate transporter dynamics:
(i) Akt2 and insulin-induced CD36 and FATP1 translocation:
Akt is known to regulate GLUT4 translocation via phospho-
rylation of AS160 [32]. In the non-phosphorylated state,
AS160 blocks GLUT4 translocation by means of its Rab-
GTPase activity, thereby keeping the Rab proteins mediating
GLUT4 translocation in an inactive state. AS160 phosphory-
lation by insulin or contraction stimulation acts to relieve
this blockade. Recently, AS160 was also shown to regulate
CD36 translocation in HL1-cardiomyocytes via inhibition of
specific Rabs [23]. FATP1 was not investigated in that study.
In the current work we observed a loss of insulin-induced
AS160 phosphorylation in Akt2-KO muscles (Fig. 2B), which
correlated with a loss of insulin-induced GLUT4 (Fig. 3B),
CD36 (Fig. 4A) and FATP1 (Fig. 4C) translocation. This may
point to a critical involvement of Akt2-mediated AS160
phosphorylation in insulin-stimulated GLUT4 and CD36
(and perhaps FATP1) translocation in muscle.
(ii) Akt2 and contraction-induced CD36 and FATP1 transloca-
tion: In contrast to the decrease in AS160 phosphorylation
in insulin-exposed muscle, AS160 phosphorylation is not
altered in contracting muscle upon Akt2 ablation. Hence,
the loss of contraction-induced CD36 (and FATP1) transloca-
tion cannot be explained at the level of AS160 regulation.
Notably, our work demonstrates that contraction-
stimulation of fatty acid transport and transporters is dis-
tinct from contraction-induced glucose transport and GLUT4
translocation. Specifically, contraction-induced glucose
transport and GLUT4 translocation are not impaired by
Akt2 ablation in muscle, whereas Akt2 is required for
contraction-stimulated fatty acid transport and FAT/CD36
and FATP1 translocation. Also previously we have reported
differences between the regulation of GLUT4 and fatty acid
transporter trafficking to the sarcolemma. These differences
appear to occur at the level of SNARE complex formation,
which is necessary for the proper fusion of transport vesicles
with their target membrane. For instance, Munc18c, a t-
SNARE-interacting protein, was established to be involved
in insulin-stimulated GLUT4 translocation to the sar-
colemma, but appeared not required for the trafficking of
any of the fatty acid transporters (FAT/CD36, FABPpm,
FATP1, -4 and -6), either in insulin-, or contraction-
stimulated skeletal muscle [33]. Furthermore, VAMP pro-
teins, a family of v-SNAREs, have been found to discriminate
between GLUT4 translocation versus FAT/CD36 transloca-
tion as well as between insulin-stimulated transporter
translocation versus contraction-induced transporter
translocation, indicating that specific VAMP isoforms are
involved in each of these processes [34]. Therefore, Akt2binding to a specific VAMP isoform might explain the differ-
ences in dependency of contraction-induced FAT/CD36 (and
possibly FATP1) translocation versus contraction-induced
GLUT4 translocation.
(iii) Akt2 and intracellular retention of FABPpm and FATP4:
another unexpected finding of the present study was that
the translocation of the various fatty acid transporters to
the sarcolemma is regulated differently by Akt2, as only
FABPpm and FATP4 sarcolemmal contents in Akt2-KO mus-
cles were increased under basal conditions with no further
increase when metabolic stimuli are applied. The molecular
mechanisms behind these differential migration patterns of
FABPpm and FATP4 versus CD36 and FATP1 in Akt2-KOmus-
cle are completely unknown. Furthermore, it remains to be
established whether the Akt2-mediated retention of
FABPpm and FATP4 is due to inhibition of their translocation
or to induction of their endocytosis.
4.3. Summary
The present study demonstrated that in muscle, both insulin
and contraction-stimulated fatty acid transport are critically
dependent on Akt2-mediated translocation of FAT/CD36 and
FATP1 to the sarcolemma. This differs from GLUT4 translocation,
which is only Akt2-dependent when stimulated with insulin but
not with muscle contraction. Akt2 regulates subcellular localiza-
tion of FABPpm and FATP4 in quite a different manner, namely
by retaining these fatty acid transporters within their subcellular
depots. Collectively, our observations reveal a previously unknown
complexity in signaling mechanisms regulating the intracellular
translocation of fatty acid transporters in skeletal muscle. Finally,
it remains to be investigated whether this Akt2-mediated short-
term regulation of fatty acid transport would impact on long-
term regulation of myocellular triglycerides and other fatty acid
metabolites.
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